Senesco Finalizes Agreement with Mayo Clinic to Study SNS01-T in Multiple Myeloma
August 24 2011 - 9:00AM
Business Wire
Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE
Amex: SNT) today announced that it has finalized a clinical trial
agreement with Mayo Clinic in Rochester, MN to study SNS01-T, the
Company’s lead therapeutic candidate for the treatment of multiple
myeloma.
Mayo Clinic is a not-for-profit medical practice and medical
research institution that is headquartered in Rochester, Minnesota.
The principal investigator in the study at Mayo is John A. Lust,
M.D., Ph.D.
The study is an open-label, multiple-dose, dose-escalation
study, which will evaluate the safety and tolerability of SNS01-T
when administered by intravenous infusion to relapsed or refractory
multiple myeloma patients. The study design calls for twice-weekly
dosing of patients for 6 weeks followed by a safety data review
period before escalating to a higher dose level in a new group of
patients. While the primary objective of the initial study is to
evaluate safety and tolerability, the effect of SNS01-T on tumor
response also will be assessed using multiple well-established
metrics including measurement of the monoclonal protein
(M-protein). The study is expected to start in the 3rd quarter of
2011.
“We are very excited to have Dr. Lust leading the effort at Mayo
to evaluate the safety and potential efficacy of SNS01-T,” stated
Leslie J. Browne, Ph.D, President and Chief Executive Officer of
Senesco Technologies Inc. Dr. Browne continued “We have
collaborated for several years with Dr. Lust to study SNS01-T and
its predecessors before selecting our lead candidate.”
About Multiple Myeloma
Multiple myeloma is an incurable cancer of plasma cells, a type
of white blood cell derived from B-lymphocytes, normally
responsible for the production of antibodies, in which abnormal
cells accumulate in the bone marrow leading to bone lesions and
interfering with the production of normal blood cells. Senesco was
previously granted orphan drug status for SNS01-T, the Company’s
lead drug candidate for treatment of multiple myeloma.
About Senesco Technologies, Inc.
Senesco Technologies is leveraging proprietary technology that
regulates programmed cell death, or apoptosis. Accelerating
apoptosis may have applications in treating cancer, while delaying
apoptosis may have applications treating certain inflammatory and
ischemic diseases. The Company is preparing to initiate a clinical
study in multiple myeloma with its lead therapeutic candidate
SNS01-T. Senesco has already partnered with leading-edge companies
engaged in agricultural biotechnology, and is entitled to earn
research and development milestones and royalties if its
gene-regulating platform technology is incorporated into its
partners’ products.
Forward-Looking Statements
Certain statements included in this press release are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Actual results could
differ materially from such statements expressed or implied herein
as a result of a variety of factors, including, but not limited to:
the ability of the Company to consummate additional financings; the
development of the Company’s gene technology; the approval of the
Company’s patent applications; the successful implementation of the
Company’s research and development programs and collaborations; the
success of the Company's license agreements; the acceptance by the
market of the Company’s products; the timing and success of the
Company’s preliminary studies, preclinical research and clinical
trials; competition and the timing of projects and trends in future
operating performance, the Company’s ability to comply with the
continued listing standards of the NYSE Amex, as well as other
factors expressed from time to time in the Company’s periodic
filings with the Securities and Exchange Commission (the "SEC"). As
a result, this press release should be read in conjunction with the
Company’s periodic filings with the SEC. The forward-looking
statements contained herein are made only as of the date of this
press release, and the Company undertakes no obligation to publicly
update such forward-looking statements to reflect subsequent events
or circumstances.
Senesco (AMEX:SNT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Senesco (AMEX:SNT)
Historical Stock Chart
From Jul 2023 to Jul 2024